Jupiter Neurosciences (JUNS) and Its Peers Financial Survey

Jupiter Neurosciences (NASDAQ:JUNS) is one of 247 publicly-traded companies in the “MED – DRUGS” industry, but how does it compare to its rivals? We will compare Jupiter Neurosciences to similar companies based on the strength of its dividends, risk, earnings, institutional ownership, valuation, analyst recommendations and profitability.

Volatility & Risk

Jupiter Neurosciences has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, Jupiter Neurosciences’ rivals have a beta of -0.49, meaning that their average stock price is 149% less volatile than the S&P 500.

Institutional & Insider Ownership

43.9% of shares of all “MED – DRUGS” companies are held by institutional investors. 50.8% of Jupiter Neurosciences shares are held by company insiders. Comparatively, 13.5% of shares of all “MED – DRUGS” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Jupiter Neurosciences and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Jupiter Neurosciences	$20,000.00	-$8.65 million	-1.50
Jupiter Neurosciences Competitors	$1.18 billion	$97.45 million	-4.75

Jupiter Neurosciences’ rivals have higher revenue and earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and target prices for Jupiter Neurosciences and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1	0	0	0	1.00
Jupiter Neurosciences Competitors	2918	4070	10355	472	2.47

As a group, “MED – DRUGS” companies have a potential upside of 123.82%. Given Jupiter Neurosciences’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Jupiter Neurosciences has less favorable growth aspects than its rivals.

Profitability

This table compares Jupiter Neurosciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-202.57%
Jupiter Neurosciences Competitors	-22,657.48%	-151.46%	-22.87%

Summary

Jupiter Neurosciences rivals beat Jupiter Neurosciences on 9 of the 13 factors compared.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.